Revia: What Patients Need To Know

Basic Revia Information

• INN (International Nonproprietary Name): Naltrexone hydrochloride.
• Brand Names Available In United States: Revia (50 mg tablets; brand discontinued in many regions), Depade (50 mg tablets; discontinued), Vivitrol (380 mg injectable, available), plus multiple generics (marketed by Teva, Sandoz, Accord Healthcare and others).
• ATC Code: N07BB04.
• Forms & Dosages: Oral tablet 50 mg (film-coated, scored; blister packs or bottles). Prolonged-release injection 380 mg vial (powder for reconstitution, single-use).
• Manufacturers In United States: Vivitrol by Alkermes; generics supplied by manufacturers including Teva, Sandoz, Accord Healthcare; Mallinckrodt was original Revia supplier (brand now discontinued in many regions).
• Registration Status In United States: FDA-approved as a prescription product for alcohol dependence and opioid relapse prevention after detox.
• OTC / Rx Classification: Prescription Only (Rx).

Key Findings From Recent Trials

Major 2022–2026 Studies

Patients and clinicians ask whether injectable naltrexone is worth the clinic visits compared with oral tablets.

Recent research from 2022 through 2026 focused on adherence and comparative effectiveness of oral naltrexone 50 mg tablets versus the monthly 380 mg intramuscular injection, Vivitrol.

The trials include head-to-head studies and pooled meta-analyses looking at alcohol use disorder and opioid relapse prevention after detoxification.

Investigators especially targeted populations with documented barriers to daily medication adherence.

Main Outcomes

Across trials, monthly extended-release injections generally showed improved adherence and retention versus daily oral dosing, particularly where forgetfulness or chaotic schedules were barriers.

For alcohol use disorder, naltrexone maintained a role in relapse prevention with reductions in heavy drinking days versus placebo or no medication in controlled trials.

In opioid use disorder, naltrexone was used for relapse prevention after detoxification, with emphasis on starting only after an opioid-free interval to avoid precipitated withdrawal.

Safety Observations

Safety findings from recent work reinforced established monitoring practices rather than identifying new major safety signals.

Hepatotoxicity remains a concern, so baseline and periodic liver function tests are advised.

Trials also repeated warnings about initiating naltrexone in the presence of opioids because of precipitated withdrawal risk.

Some studies tracked mood and psychiatric outcomes, advising vigilance in patients with depression or suicidal ideation.

Clinical Mechanism Of Action

Layman’s Explanation

People often ask how naltrexone stops drinking or drug relapse.

Naltrexone blocks opioid receptors in the brain so alcohol or opioids produce less pleasure and reinforcement.

When pleasurable effects are blunted, cravings usually decrease and the chance of relapse falls over time when medication is paired with counseling.

Scientific Breakdown

Primary Receptor Action

Naltrexone is a competitive antagonist at mu-opioid receptors.

It binds without activating the receptor, preventing endogenous opioids and opioid drugs from producing euphoria.

Secondary Effects

By blocking opioid receptors, naltrexone indirectly reduces alcohol-induced dopamine surges in the mesolimbic reward circuitry.

This modulation of reward pathways helps lower cue-driven craving for alcohol or opioids.

Pharmacokinetics

Oral 50 mg tablets provide daily systemic exposure with peak-and-trough plasma levels each day.

The 380 mg intramuscular Vivitrol formulation releases drug slowly over roughly four weeks to sustain receptor blockade.

ATC classification N07BB04 groups naltrexone among drugs used in alcohol dependence.

Scope Of Approved And Off-Label Use

United States Approvals

Clinicians frequently confirm that both oral and injectable forms are approved for specific uses.

In the United States, the FDA approves naltrexone for relapse prevention in opioid dependence after detoxification and for alcohol dependence.

Available formulations include 50 mg oral tablets (generics widely available) and the 380 mg prolonged-release intramuscular injection, Vivitrol.

Revia was the historical 50 mg brand, but the brand is discontinued in many regions while generics remain available.

Notable Off-Label Trends

Off-label exploration has increased in behavioral and addictive phenotypes, such as gambling disorder and some impulse-control problems.

Smaller trials and case series also examine naltrexone as adjunctive therapy for binge-eating behaviors and as an adjunct in chronic pain settings, but evidence is limited.

Naltrexone combined with bupropion is an approved product (Contrave) for weight management, but standalone naltrexone for weight loss is investigational.

Dosage Strategy

General Dosing

Patients often want a simple dosing plan so adherence becomes realistic.

Standard adult oral dosing is 50 mg once daily using the film-coated scored tablet formulation.

For people with adherence difficulties, the prolonged-release 380 mg intramuscular injection (Vivitrol) is given once every four weeks.

Condition-Specific Dosing

Alcohol Use Disorder

Typical initiation uses 50 mg orally once daily.

Treatment commonly continues for a minimum three to six months and is individualized according to response and psychosocial supports.

Opioid Use Disorder

Oral 50 mg daily or 380 mg IM monthly are options, but treatment must start after successful detox.

Patients should be opioid-free for typically seven to ten days before starting to avoid precipitated withdrawal.

Duration for relapse prevention can be indefinite and should be reassessed regularly.

Dose Adjustments And Special Populations

Safety and effectiveness in children under 18 are not established, so use is not recommended for pediatric patients.

Elderly patients require caution and monitoring of renal and hepatic function; no routine dose reduction is specified but clinical judgment is needed.

Naltrexone is contraindicated in acute hepatitis or liver failure and requires monitoring in moderate hepatic or renal impairment.

Missed dose instructions: take when remembered unless it is near the next scheduled dose; do not double the dose.

Safety Protocols

Contraindications

Start by asking whether a patient has used opioids recently.

Do not initiate naltrexone when opioids are present, since this can precipitate acute withdrawal.

Do not use in acute hepatitis or significant hepatic impairment.

Known hypersensitivity to naltrexone or its excipients is an absolute contraindication.

Pregnancy labeling varies by region, and use in pregnancy requires careful risk/benefit evaluation.

Adverse Effects

Common side effects are typically mild to moderate and often improve with time.

These include nausea, headache, insomnia, joint or muscle pain, anxiety, tiredness, and loss of appetite.

Serious concerns focus on hepatotoxicity, which has been reported and appears dose-related in some cases.

Baseline liver function tests and periodic monitoring are recommended to detect hepatic injury early.

Patients with a history of depression or suicidal ideation require closer psychiatric monitoring while on therapy.

Interaction Mapping

Food Interactions

Many patients ask whether they must take naltrexone with food.

There are no major food-drug interactions requiring special meals for oral tablets, but taking medication at a consistent daily time is advised.

The intramuscular 380 mg Vivitrol bypasses gastrointestinal absorption, so food is irrelevant for that formulation.

Drug Combinations To Avoid

Concurrent use with opioid agonists or partial agonists is contraindicated because naltrexone will block analgesic and euphoric effects.

Opioid-containing cough suppressants and combination pain products should be avoided unless medically necessary and supervised.

Coadministration with hepatotoxic medications should prompt closer liver function monitoring.

Emergency pain management with opioids is complex in patients receiving naltrexone; clinicians should plan analgesia strategies or consider washout when appropriate.

Always reconcile all prescription, over-the-counter, and herbal products before starting naltrexone.

Patient Experience Analysis

Survey Data

Patients frequently report better adherence with monthly injections compared with daily tablets, especially where daily routines are unstable.

Clinic audits and observational cohorts echo trial results: Vivitrol improves retention for some patients while oral 50 mg tablets remain well tolerated for others.

Reported side effects in surveys match clinical trial profiles: transient nausea, headache, sleep disturbance, and joint aches.

Those with hepatic concerns commonly request close lab monitoring before and during treatment.

Forum Trends

Online forums often discuss initiation anxiety, especially fear of precipitated withdrawal when switching from opioids.

Many patients describe relief from cravings once therapeutic blockade is established.

Access barriers and stigma are common themes, and some patients prefer oral tablets where clinic visits for injections are a problem.

Clinicians should validate these lived experiences and set realistic expectations about side effects and monitoring requirements.

Distribution And Pricing Landscape

Key Manufacturers And Brands

Vivitrol is produced by Alkermes and remains commercially available globally.

Generic oral naltrexone tablets are supplied by manufacturers such as Teva, Sandoz, and Accord Healthcare.

Mallinckrodt was the original supplier of Revia, though the brand is discontinued in many regions.

Local manufacturers in Eastern Europe, India, and Asia may label products as Naltrexona or similar names.

Market Trends

With the branded Revia discontinued in many markets, generic oral naltrexone availability has expanded and generally improved affordability.

Vivitrol occupies a niche for patients who need or prefer supervised monthly dosing, and pricing and reimbursement policies heavily influence uptake.

Clinicians and pharmacies should verify local registration and formulary status when sourcing supply.

In our online pharmacy, revia is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

Comparison Table (Oral/Injectable—By Indication, Mechanism, Pros/Cons)

Below is a compact textual comparison to help selection when naltrexone is considered alongside alternatives.

• Naltrexone (Oral 50 mg / Vivitrol 380 mg IM): Indications—alcohol dependence and opioid relapse prevention after detox. Mechanism—opioid receptor antagonist. Pros—reduces craving and relapse risk; injectable improves adherence. Cons—contraindicated with current opioid use; hepatotoxicity risk.
• Disulfiram: Indication—alcohol dependence. Mechanism—produces aversive reaction to ethanol. Pros—strong deterrence effect if taken as prescribed. Cons—adherence problems and safety concerns if alcohol is consumed.
• Acamprosate: Indication—alcohol dependence. Mechanism—modulates glutamate and GABA systems. Pros—fewer hepatic concerns compared to naltrexone. Cons—requires renal dosing adjustments.
• Buprenorphine/Suboxone, Methadone: Indication—opioid dependence. Mechanism—partial or full opioid agonists. Pros—robust evidence for opioid use reduction and withdrawal management. Cons—regulatory controls and potential for misuse.
• Nalmefene: Indication—alcohol dependence in some regions. Mechanism—opioid receptor antagonist similar to naltrexone. Pros—alternative antagonist option. Cons—regional approval varies.

Pros And Cons

Naltrexone is a core medication-assisted treatment option for patients who are opioid-free and prefer a non-agonist strategy.

Alternatives like agonist therapies (buprenorphine, methadone) are often more suitable for patients in active opioid dependence or needing maintenance therapy.

Choice depends on patient goals, hepatic and renal status, access, and the ability to attend clinic visits.

Regulatory Status

Global Approvals And ATC Classification

Naltrexone hydrochloride has ATC code N07BB04 and is approved by the FDA and EMA for alcohol dependence and opioid relapse prevention after detox.

Vivitrol retains global availability as the branded prolonged-release injectable made by Alkermes.

Generics supply the oral 50 mg tablet market in many regions.

Prescription Controls

Naltrexone is prescription-only (Rx) in the United States and the European Union.

Regulatory labels consistently require confirmation of opioid abstinence before initiation and recommend baseline and periodic liver function testing.

Prescribers should consult local formularies and product labeling for up-to-date prescribing information and reimbursement rules.

Consolidated FAQ

Common Patient And Clinician Questions

Q: What is Revia?

A: Revia is a brand name for naltrexone 50 mg tablets; the brand is discontinued in many regions while generic naltrexone tablets are widely available. Vivitrol is the 380 mg intramuscular prolonged-release formulation.

Q: When can naltrexone be started after opioids?

A: Start only after being opioid-free for typically seven to ten days to avoid precipitated withdrawal, and confirm abstinence clinically before initiation.

Q: How long should treatment continue?

A: For alcohol dependence a minimum of three to six months is common; for opioid relapse prevention the duration is individualized and may extend for years with regular reassessment.

Q: What monitoring is required?

A: Baseline and periodic liver function tests are required, plus psychiatric monitoring for mood changes and safety counseling about opioid avoidance while on therapy.

Q: What if a dose is missed or overdosed?

A: Missed dose—take when remembered unless it is close to the next scheduled dose; do not double. Overdose—seek emergency care; watch for signs of hepatotoxicity or liver failure.

Visual Guide

Suggested Visuals For Clinicians And Patients

Mechanism Diagram

Use a simple brain schematic that shows mu-opioid receptor blockade and a reduced dopamine surge to explain how naltrexone reduces craving.

Dosing Flowchart

Create a decision tree for oral versus injectable choices that includes prerequisites such as opioid-free interval (7–10 days), baseline labs, monitoring intervals, and follow-up scheduling.

Monitoring Timeline

Design a timeline indicating baseline liver function testing, checks at one to three months, and periodic reassessment thereafter, with red-flag icons for hepatotoxicity signs and mood changes.

Storage/Handling Icons

Patient handouts should include tablet storage icons (20–25°C; protect from moisture/heat) and injection cold-chain icons (refrigerate before reconstitution; single-use vial).

Design Callouts

Keep patient materials low-literacy, use plain language, and include contact details for urgent concerns.

Clinician visuals can include the ATC code N07BB04, dosage tables, contraindication alerts, and references to regulatory product information.

Storage And Transport

Conditions For Tablets

Store oral tablets at 20–25°C (68–77°F) and protect from moisture and excessive heat.

Typical packaging includes film-coated scored tablets in blister packs or bottles; check local labeling for exact shelf-life and stability information.

Injection Handling

Vivitrol is usually supplied as a powder for reconstitution in single-use vials and should be refrigerated prior to reconstitution.

Use reconstituted vial contents within the manufacturer-recommended timeframe and follow cold-chain procedures during transport.

Clinics must maintain temperature logs and follow disposal guidance for unused or reconstituted products.

Guidelines For Proper Use

Initiation And Monitoring Checklist

• Confirm indication: alcohol dependence or opioid relapse prevention post-detox.
• Ensure opioid-free interval of typically seven to ten days before starting.
• Obtain baseline liver function tests and assess psychiatric history for depression or suicidal ideation.
• Choose formulation based on adherence risks, access, and patient preference: oral 50 mg daily or Vivitrol 380 mg IM monthly.
• Schedule follow-up visits and periodic LFT monitoring, and provide an emergency plan for overdose or hepatic symptoms.

Practical Counseling Points

Emphasize that naltrexone blocks opioid effects, and that any need for opioid analgesia should be communicated to the prescribing clinician.

Discuss common side effects such as nausea and headache and reassure patients that many side effects subside with continued use.

Reinforce the importance of psychosocial support and that treatment duration is individualized.

Clarify missed-dose instructions and that doubling up is not advised.

Delivery Across United States